Little “Sheng” Has a Reason Learning Hall | TDCC Experimental Skills Intensive Training Course
Release Date:
2025-09-15 15:37
With the rapid advancement of cancer immunotherapy, novel therapeutic modalities such as bispecific antibodies, immune cell engagers, and adoptive cell therapies have emerged one after another. A core mechanism underlying these approaches is the redirection and activation of T cells to achieve specific cytotoxicity against tumor cells. T cell-dependent cytotoxicity ( T cell-dependent cellular cytotoxicity, TDCC ) Real Assay, as the “gold standard” for evaluating the in vitro efficacy of such drugs, plays a critical role in drug screening, mechanistic studies, and preclinical evaluation.
TDCC is a cytotoxic response that relies primarily on CD3+ T cells, and its activity is regulated not only by positive activation signals but also by inhibitory signals, such as the PD-1/PD-L1 pathway. Blocking this pathway with PD-1/PD-L1 antibodies can markedly enhance T cell–mediated tumor killing.
A typical TDCC assay is a three-component co-culture system comprising effector cells (typically human peripheral blood mononuclear cells [PBMCs] or purified T cells), target cells (tumor cell lines expressing a specific antigen), and the test drug (such as a bispecific antibody or a T-cell engager). This assay mimics the formation of the immunological synapse in vivo: the drug molecule acts as a “bridge,” with one arm binding to CD3 on the T-cell surface and the other arm binding to the target antigen on the tumor cell, thereby triggering T-cell activation and the release of effector molecules such as perforin and granzymes, or inducing target-cell apoptosis via the Fas/FasL pathway. At the same time, activated T cells secrete large amounts of cytokines—including IFN-γ, IL-2, and TNF-α—further amplifying the immune response.
The TDCC assay serves as a critical bridge between molecular design and in vivo efficacy, providing a core in vitro evaluation platform for the development of T-cell–redirecting therapeutics. By precisely quantifying target cell killing and T-cell activation, this model has significantly advanced the field of cancer immunotherapy and continues to drive innovative drug discovery.
To express our gratitude to both new and existing customers, Hycells Biotechnology has joined forces with InnoCell to launch an in-person hands-on training course centered on the theme of TDCC. This training program leverages the complementary strengths of both organizations, integrating Hycells’s state-of-the-art cell sample bank with InnoCell’s high-quality sorting reagent kits to provide a comprehensive, systematic overview of the entire TDCC experimental workflow. The course will delve into the underlying principles of the experiments, detailed operational procedures, and strategies for addressing common challenges, while hands-on, step-by-step instruction will reinforce participants’ technical skills and their ability to solve real-world problems. In addition, expert instructors will be on hand to answer questions and facilitate discussions on typical issues such as the following:
1. What states and criteria must effector cells and target cells meet to achieve optimal cytotoxicity?
2. How should the effector-to-target cell ratio (E:T) be set?
3. Does higher in vitro cytotoxic activity of bispecific antibodies necessarily translate into better clinical outcomes?
We warmly welcome colleagues in drug discovery and development to join the exchange and jointly enhance our capabilities!
Training Program Overview
Co-organized : Hycells Bio & InnoScience
Training Participants : R&D personnel, laboratory technicians, and other professionals at universities, research institutes, hospitals, and large pharmaceutical companies.
Training scale To ensure the effectiveness of the hands-on demonstration, each session is limited to 10 participants.
Training Time : September 13, 2025
Training Location : Hycells Shanghai Conference Room (Room 503, Building 2, No. 999 Jiangyue Road)
Training Topic : TDCC Experiment
Training fees ： Free of charge (Hycells will cover training fees, textbook costs, laboratory consumables, lunch, and tea breaks; transportation and accommodation are at the client’s own expense).
Training Program Schedule
|
Time |
Schedule |
|
09:00-09:30 |
Check-in and Entry |
|
09:30-10:30 |
Theory 1: Detailed Experimental Protocol for CD3+ T Cell Sorting |
|
10:30-11:30 |
Theory 2: Detailed Explanation of the TDCC Experimental Procedure |
|
11:30-13:30 |
Lunch & Break |
|
1:30 PM–2:30 PM |
Practical Exercise 1: Standardized Revival of Cryopreserved PBMC Samples CD3+ T Cell Sorting Protocol Demonstration Key Technical Points and Common Problem Analysis for Sorting Kit Use |
|
14:30-15:30 |
Practical Exercise 2: Demonstration of the TDCC Standard Process, Results, and Key Insights from Validation Data Analysis |
|
4:00 PM |
Training completed |
Speaker Biography
Zhang Yingbo
Head of the Technical Department at Hycells
Proficient in the field of macromolecular therapeutics, with more than 10 years of extensive technical service experience in oncology immunotherapy, ophthalmic diseases, and vaccine development. Previously served as a Senior Scientist and Project Leader in the Biologics Drug Discovery Services Department at WuXi Biologics Shanghai Co., Ltd. 。
Currently serves as the Head of the Technical Department at Shanghai Hycells Biotechnology Co., Ltd., with full responsibility for R&D, technical services, and production management. His expertise spans the entire antibody drug development pipeline, from early-stage target identification and in vitro/in vivo efficacy evaluation to preclinical studies (PCC). He is particularly skilled in establishing immunogenicity assessment platforms, managing CRO projects, and integrating multiple technology platforms, and is capable of independently initiating projects, conducting feasibility analyses, and leading cross-functional teams to execution. In terms of management, he has led a 20-person technical team, excelling in cross-departmental collaboration, building standardized R&D and manufacturing systems, and constructing laboratories to P2/GLP standards. He is adept at formulating R&D strategies, optimizing pipeline prioritization, and driving project implementation. He has repeatedly spearheaded customer technical exchanges, internal training sessions, and project presentations, demonstrating exceptional communication and organizational skills.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board